Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

Sarepta Therapeutics (SRPT) is suspending shipments of ELEVIDYS for non-ambulatory Duchenne muscular dystrophy patients and pausing its ENVISION study after a second reported case of acute liver failure resulting in death. The company is developing an enhanced immunosuppressive regimen with expert consultation and regulatory engagement, including sirolimus, to mitigate the risk. Shipments for non-ambulatory patients will remain suspended until the enhanced regimen is approved and implemented, while no changes are proposed for ambulatory patients.

Analysis

Sarepta Therapeutics (NASDAQ:SRPT) has issued a significant safety update for its Duchenne muscular dystrophy gene therapy, ELEVIDYS, following a second reported fatal case of acute liver failure (ALF) in a non-ambulatory patient. This development, underscored by a strongly negative sentiment score (-0.65) and a high market impact score (0.7) for the company, has prompted Sarepta to suspend ELEVIDYS shipments for infusions in non-ambulatory patients and voluntarily pause its ENVISION clinical study (Study SRP-9001-303), which serves as the confirmatory trial for this patient group, an action with which the FDA concurs. The company is now actively developing an enhanced immunosuppressive regimen, potentially incorporating sirolimus and supported by preclinical data, in consultation with a panel of multi-disciplinary clinical experts and regulatory bodies, aiming to mitigate this serious liver toxicity risk. While the treatment protocol for ambulatory patients currently remains unchanged, the suspension for non-ambulatory patients and the ENVISION study pause introduce considerable uncertainty regarding the timeline for full market access and regulatory validation in this segment. Sarepta has stated that elevated liver enzymes are a known class effect of AAV-based gene therapies, with the exact mechanism of AAV-related liver toxicity potentially driven by an adaptive immune response, and this event will inform discussions about a potential label update. An investor call is scheduled for June 16, 2025, to provide further updates.

Key Decisions for Investors

• Investors should closely monitor Sarepta's forthcoming communications, particularly the June 16, 2025 investor call, for updates on the proposed enhanced immunosuppressive regimen, feedback from regulatory agencies like the FDA, and the projected timeline for resuming ELEVIDYS shipments to non-ambulatory patients and the ENVISION study.
• Re-evaluate risk exposure to SRPT, considering the direct impact of the shipment suspension and clinical trial pause on ELEVIDYS's revenue potential and market penetration in the non-ambulatory Duchenne patient segment, which was under an accelerated approval pathway requiring confirmatory trial data.
• Anticipate potential stock volatility and scrutinize any revisions to Sarepta's guidance, as these safety concerns and subsequent actions could lead to a label update for ELEVIDYS, affecting its overall risk-benefit profile and physician adoption.